Medios AG is closing the facility of its wholly owned subsidiary, Medios Solutions Aschaffenburg GmbH, as part of an optimization of its manufacturing network. The company is consolidating patient-specific manufacturing at its remaining locations across Germany, a move aimed at countering sustained margin pressure in the business of patient-specific formulations, particularly due to price regulatory adjustments.
Production has already been relocated, and supplies to pharmacies and hospitals are guaranteed, according to the company. The Aschaffenburg site most recently accounted for approximately 10% of the production volume of the Medios Group’s German manufacturing facilities. The measure affects 32 employees, for whom Medios is seeking to provide fair compensation.
The company operates a network of six GMP manufacturing facilities for patient-specific therapies in Germany. GMP stands for “Good Manufacturing Practice,” which entails mandatory production standards and validated quality management. The Aschaffenburg site had recently been operating at below-average profitability amid declining capacity utilization. Continued economic operation was no longer feasible, and structural renovation work required at the site accelerated the implementation of the decision.
The site closure is part of the company’s Operational Excellence Program, which aims to sustainably strengthen profitability. Thomas Meier, CEO of Medios AG, stated: “With a view to ensuring a reliable supply for our customers and maintaining capacity utilization at all sites, we are now optimizing our successful regional presence strategy and consistently developing it further. With Mannheim and Stuttgart, we have two high-performing Medios sites in southern Germany, ensuring that a reliable supply is maintained.”
Medios AG is a leading provider of Specialty Pharma in Europe, with locations in Germany, the Netherlands, Belgium, and Spain. The company supports key partners in the supply chain with innovative solutions and intelligent services, focusing on pioneering individualized medicine to make innovative therapies available to pharmacies, specialist practices, and pharmaceutical companies. Medios AG is Germany's first listed specialty pharmaceutical company, with shares listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and included in the SDAX selection index.
Important events for the Medios Group in the 2026 financial year include the Half-Year Financial Report on August 12, the Berenberg and Goldman Sachs 15th German Corporate Conference in Munich from September 21 to 23, the Medios Capital Markets Day in Breda on September 28/29, and the Quarterly Statement as of September 30 on November 10.
For more information, visit www.medios.group.
